Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2019 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2019

Reaffirms full year 2019 financial forecast and operational goalsProvides Q3 2019 revenue forecast of $245M-$275M GAITHERSBURG, Md., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc....
July 30, 2019 16:42 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile

GAITHERSBURG, Md., July 30, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its...
July 18, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Release Second Quarter 2019 Financial Results and Conduct a Conference Call on August 1, 2019

GAITHERSBURG, Md., July 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, August 1, 2019 at 5:00 pm (Eastern Time) to discuss the financial...
June 05, 2019 15:16 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions kündigt FDA-Zulassung für Änderung bei Lagerbedingungen und Produktionsverlagerungen für seinen Cholera-Impfstoff an

GAITHERSBURG, Md., June 05, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) hat heute die Zulassung durch die US-amerikanische Lebensmittel- und Arzneimittel-Überwachungsbehörde „U.S....
June 04, 2019 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine

GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced approval by the U.S. Food and Drug Administration (FDA) of the Prior Approval Supplement...
June 03, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness

GAITHERSBURG, Md., June 03, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response...
May 20, 2019 16:05 ET | Source: Emergent Biosolutions, Inc.

A Emergent BioSolutions anuncia a concessão de autorização de introdução no mercado em cinco países da UE da sua vacina por via oral contra a febre tifoide; expande a disponibilidade na Europa

GAITHERSBURG, Maryland, May 20, 2019 (GLOBE NEWSWIRE) -- A Emergent BioSolutions Inc. (NYSE: EBS) anunciou hoje que foi bem-sucedida na obtenção da autorização de introdução no mercado da sua vacina...
May 20, 2019 16:05 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions gibt Genehmigung der Marktzulassung in fünf EU-Ländern für seinen oralen Typhus-Impfstoff bekannt; Ausweitung der Verfügbarkeit in Europa

GAITHERSBURG, Maryland, May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) gab heute bekannt, dass es erfolgreich die Marktzulassung für seinen oralen Typhus-Impfstoff...
May 20, 2019 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe

GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine...
May 20, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Participate in Series of Investor Conferences

GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following...